Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Market Cap
From what 0 stock analysts predict, the share price for (MORF) might decrease by NAN% in the next year. This is based on a 12-month average estimation for MORF. Price targets go from $ to $. The majority of stock analysts believe MORF is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
has a total of 0 Wall St Analyst ratings. There are 0 buy ratings, 0 ratings, and 0 sell ratings. Since most analysts have a sell consensus rating, the expectation is that will perform worse than the market. Investors shouldn't rely purely on analyst ratings; we encourage investors to also take a look at the fundamental and technical analysis in their due diligence.
These are the latest 20 analyst ratings of MORF.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
Data Not Found! | ||||
In 2023, MORF generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that MORF's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Fri, 16 Aug 2024
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Eli Lilly has acquired Morphic Holding, enhancing its immunology pipeline with oral integrin therapies like MORF-057 for inflammatory bowel disease, aligning with its gastroenterology strategy.
Why It Matters - Eli Lilly's acquisition of Morphic expands its immunology portfolio, enhancing growth potential in gastroenterology and positioning it to lead in emerging therapies for chronic diseases.
Sun, 11 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (NASDAQ:MORF) and Eli Lilly (NYSE: LLY). Investors holding Morphic are encouraged to seek more information.
Why It Matters - The investigation into Morphic's merger with Eli Lilly may indicate potential legal or regulatory issues, affecting stock performance and investor confidence in both companies.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (NASDAQ:MORF) and Eli Lilly (NYSE:LLY). Investors are encouraged to seek more information.
Why It Matters - The investigation into the Morphic and Eli Lilly merger could impact stock valuations, investor confidence, and potential regulatory outcomes, influencing trading decisions.
Fri, 09 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (MORF) and Eli Lilly (LLY). Investors are encouraged to visit their site for more details.
Why It Matters - The investigation into Morphic's merger with Eli Lilly could indicate potential legal or regulatory issues, impacting investor sentiment and stock performance for both companies.
Thu, 08 Aug 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (NASDAQ: MORF) and Eli Lilly (NYSE: LLY). Investors are encouraged to seek more information.
Why It Matters - The investigation into Morphic's merger with Eli Lilly may signal potential legal issues, impacting stock performance and investor confidence in both companies.
Mon, 05 Aug 2024
Sentiment - NEUTRAL
Source - Accesswire
Summary - Bronstein, Gewirtz & Grossman, LLC is investigating the merger between Morphic Holding, Inc. (NASDAQ:MORF) and Eli Lilly (NYSE: LLY). Current Morphic investors can find more info at bgandg.com/MORF.
Why It Matters - The investigation into the Morphic and Eli Lilly merger may signal potential legal or financial issues, affecting stock prices and investor sentiment regarding Morphic.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
